SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Presented By Mario Sznol at 2014 ASCO Annual Meeting

roy avatar
roy
18 diapositives · 367 Views · Jul 31, 2014

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL) . Presented By Mario Sznol at 2014 ASCO Annual Meeting. Disclosures.

#presented by mario sznol at 2014 asco annual meeting #presented by mario sznol at 2014 asco annual meeting ppt #powerpoint #presentation
Presented By Mario Sznol at 2014 ASCO Annual Meeting - slide 1
01 / 18Presented By Mario Sznol at 2014 ASCO Annual Meeting
1 / 17

Télécharger la présentation

Presented By Mario Sznol at 2014 ASCO Annual Meeting
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL) Presented By Mario Sznol at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Mario Sznol at 2014 ASCO Annual Meeting

  3. Ipilimumab and Nivolumab Clinical Experience in Patients with Advanced Melanoma Presented By Mario Sznol at 2014 ASCO Annual Meeting

  4. Objectives Presented By Mario Sznol at 2014 ASCO Annual Meeting

  5. CA209-004 Phase I Study: Dose Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

  6. Patient Demographics Presented By Mario Sznol at 2014 ASCO Annual Meeting

  7. Activity Summary: Concurrent and Sequenced Cohorts from 004 Presented By Mario Sznol at 2014 ASCO Annual Meeting

  8. Response in Target Lesions Presented By Mario Sznol at 2014 ASCO Annual Meeting

  9. Slide 9 Presented By Mario Sznol at 2014 ASCO Annual Meeting

  10. Characteristics of Response Presented By Mario Sznol at 2014 ASCO Annual Meeting

  11. Safety Overview Presented By Mario Sznol at 2014 ASCO Annual Meeting

  12. ORR by BRAF Status for Concurrent Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

  13. ORR by PD-L1 Status (5% cutoff) Presented By Mario Sznol at 2014 ASCO Annual Meeting

  14. ORR by Ipilimumab Exposure at Time <br />of Nivolumab Treatment Presented By Mario Sznol at 2014 ASCO Annual Meeting

  15. Overall Survival for Concurrent <br />Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

  16. Survival Endpoints for Concurrent and Sequential Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

  17. Conclusions Presented By Mario Sznol at 2014 ASCO Annual Meeting

  18. Acknowledgments Presented By Mario Sznol at 2014 ASCO Annual Meeting